Cardinal Health and McKesson moved to extend CVS Health distribution deals through June 2032, retaining their largest customer pending final contracts.
|Articles|August 4, 2021
BMS finalizes sale of European facility
WuXi STA will take reigns of the operations, as CDMO expands
Advertisement
Bristol Myers Squibb (BMS) has officially completed the
As part of the deal, WuXi STA is acquiring the Couvet site’s operations and assets, which include the plant and equipment, as well as inheriting a technically experienced workforce.
The Couvet site is located in the canton of Neuchâtel, Switzerland. It is a state-of-the-art manufacturing facility with commercial-scale production capacity for capsule and tablet dosage forms.
Advertisement
Related to this article
As more pharmacies dispense GLP-1s, payment processor reviews, higher fees and account closures are emerging as an overlooked point of friction in the access channel.
Eutecma's Tempaid buy pairs reusable bulk shippers with last-mile mailers as smaller, more frequent refrigerated shipments reshape demand.
Twenty-six manufacturers now hold most-favored-nation agreements, and the commitments attached to the pricing terms may matter more than the prices themselves.
LogiPharma's Charleen Ring and McKesson's Chris Van Norman preview the 2026 agenda, sessions to prioritize and a day two fireside chat.
Inside the October 2026 issue: why splitting MMR takes years, why payers cite a price that does not bind them, and what pricing rules broke.
Mike Hennessy Jr. on the commercial assumptions being rewritten across pricing, patient engagement and supply chain in PC's October 2026 print issue.
In this Q&A, Doceree CEO Harshit Jain, MD, explains why AI should inform prescribing decisions, not drive them, and how sales reps own relationships while AI extends reach.
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
Cardinal Health, McKesson Extend CVS Distribution Deals to 2032
2
What to Watch at LogiPharma: Resilience, Practical AI and New Peer Formats
3
Pharma Pulse: EU's Pharma Package and Specialty Drug Tariff Exemptions
4
How the GLP-1 Boom Stress-Tests the Pharma Cold Chain
5